Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2.

Details

Title
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
Author
Basile, Kerri 1   VIAFID ORCID Logo  ; Rockett, Rebecca J 2 ; McPhie, Kenneth 3 ; Fennell, Michael 1 ; Johnson-Mackinnon, Jessica 4   VIAFID ORCID Logo  ; Agius, Jessica E 4 ; Fong, Winkie 4 ; Rahman, Hossinur 1 ; Ko, Danny 1 ; Donavan, Linda 1 ; Hueston, Linda 5 ; Lam, Connie 4 ; Arnott, Alicia 1 ; Chen, Sharon C-A 6 ; Maddocks, Susan 1 ; Matthew V O’Sullivan 6 ; Dwyer, Dominic E 6 ; Vitali Sintchenko 6 ; Kok, Jen 7   VIAFID ORCID Logo 

 Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia 
 Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Sydney, NSW 2145, Australia; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW 2006, Australia 
 Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2145, Australia 
 Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Sydney, NSW 2145, Australia 
 Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, QLD 4222, Australia 
 Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Sydney, NSW 2145, Australia; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW 2006, Australia 
 Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia; Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Sydney, NSW 2145, Australia 
First page
2023
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
19994915
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2716588532
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.